CYD-4-61

Cat. No.: HY-148368: FAQs
Data Sheet Handling Instructions Technical Support

CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.

For research use only. We do not sell to patients.

CYD-4-61 Chemical Structure

CAS No. : 1425944-33-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Bax

Cellular Effect

Cell Line	Type	Value	Description	References
MCF-10A	IC₅₀	0.11 μM Compound: CYD-4-61	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]
MCF7	IC₅₀	0.06 μM Compound: CYD-4-61	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]
MDA-MB-231	IC₅₀	0.07 μM Compound: CYD-4-61	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]

In Vitro

CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC₅₀s of 0.07 µM against triple-negative breast cancer MDA-MB-231 and 0.06 µM against ER-positive breast cancer MCF-7 cell lines, respectively^[1].
CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells^[1].
CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells^[1].
CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MCF-10A, T47D, MCF-7, MDA-MB-231, and MDA-MB-468 cells
Concentration:	0.1, 1, and 10 μM
Incubation Time:	72 hours
Result:	Inhibited triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation and viability.

Western Blot Analysis^[1]

Cell Line:	MCF-7 and MDA-MB-231 cells
Concentration:	5 μM
Incubation Time:	0, 6, 12, 24, and 48 hours
Result:	Dose-dependently led to the upregulation of cleaved PARP-1, cleaved caspase 3, and downregulation of cyclin D1.

In Vivo

CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Triple-negative breast cancer MDA-MB-231 xenograft model in mice^[1]
Dosage:	2.5 mg/kg
Administration:	Intraperitoneal injection; once daily for 7 consecutive days
Result:	Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%.

Molecular Weight

359.38

Formula

C₂₁H₁₇N₃O₃

CAS No.

1425944-33-7

SMILES

NCCOC1=NC=CC=C1/C=C2C3=C(C4=C/2C=CC=C4)C=CC([N+]([O-])=O)=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Liu G, et al. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. Eur J Med Chem. 2019 Sep 15;178:589-605. [Content Brief]

CYD-4-61 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CYD-4-611425944-33-7Bcl-2 FamilyApoptosistriple-negative breast cancer MDA-MB-231ER-positive breast cancer MCF-7 cellcytochrome cInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *